Despite $2.5 million placeholder price tags, the Institute for Clinical and Economic Review draft evidence report considers gene therapy cost-effective versus comparators in both hemophilia A and B.

Please note that the posts on The Blogs are contributed by third parties. The opinions, facts and any media content in them are presented solely by the authors, and neither The Times of Israel nor its ...

Remediation methods capable of combating the ‘forever chemicals’ crisis have been laid out in a new evidence report on PFAS (pictured right). The unveiling of the document comes just months after we ...

A Biologics License Application has been submitted to the FDA review for sotatercept in the treatment of pulmonary arterial hypertension. Sotatercept shows promise in the treatment of pulmonary ...